Back to mobile site

Mylan (MYL) and Biocon Announce FDA Approval for Ogivri to Treat HER2-Positive Breast and Gastric Cancers

December 1, 2017 11:33 AM EST Send to a Friend
Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login